Navigation Links
AnGes in Medical Technology

Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial

SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced the receipt of a $2.1 million cash payment from AnGes MG, Inc. for costs associated with the ongoing Allovectin-7(R) Immunotherapeutic for Metastatic Melanoma (AIMM) Phase 3 trial. AnGes is fundi...

BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health

NOVATO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has submitted a Biologics License Application (BLA) for Naglazyme(R) (galsulfase) to the Ja...

Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan

SAN DIEGO, June 18, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that the company's licensee, AnGes MG, Inc. reported positive results following interim analysis of data from the first 41 subjects to complete a Phase 3 trial of an angiogenesis product candidate using Vical's D...

Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey

...nd is currently enrolling patients in the United States, Canada and Europe. anges MG, Inc., is funding the clinical trial under a collaborative agreement wit...f at all; whether Vical will receive all of the clinical trial funding from anges under the collaborative agreement; whether Allovectin-7(R) or any other pro...

Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial

...llion of cash payments and equity investments from anges MG, Inc., under a previously announced collaborati...altrial.com . In exchange for funding the trial, anges received exclusive marketing rights in Japan and o...les levels are achieved. Vical is obligated to pay anges tiered royalties based on defined sales levels in ...

Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report

...nd is currently enrolling patients in the United States, Canada and Europe. anges MG, Inc., is funding the clinical trial under a collaborative agreement wit...tin-7(R); whether Vical will receive all of the clinical trial funding from anges under the collaborative agreement, which will depend on continued developme...

Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs

... Development Programs -- The company's licensee, anges MG, Inc. (AnGes), reported positive results fo...n of an Independent Data Monitoring Committee, anges ended the trial early and is preparing an applicat... metastatic melanoma. The trial is being funded by anges under a collaborative agreement with Vical. ...
AnGes in Biological Technology

Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program

SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) and AnGes MG, Inc., have signed a non-binding Letter of Intent indicating their mutual interest to license the development and marketing rights for Vical's pandemic influenza DNA vaccines in Japan to AnGes. AnGes pla...

Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product

SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced the company's licensee, AnGes MG, Inc., reported submission on March 27, 2008, of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare for its angiogenesis product ca...

Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs

...e results of an interim analysis in this trial on those subjects who were enrolled by the end of March. H5N1 Pandemic Influenza Vaccines Vical and anges MG, Inc., signed a non-binding Letter of Intent in October indicating their mutual interest in licensing the development and marketing rights for Vica...

World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc.

...ses of biotech, pharmaceutical companies, research, and academic institutions. Leading biotech companies operating in gene therapy marketplace include anges MG Inc, Cell Genesys, GenVec, Genzyme Corporation, Introgen Therapeutics Inc, Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd, Targeted Genetics ...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...RMA SA (Euronext, Brussels: OME) PHOTOCURE ASA (Oslo, Norway: PHO) QLT INC. (TSE: QLTI) SINCLAIR PHARMA PLC (London Main Market, U.K.: SPH) Add anges MG INC (Tokyo SE: 4563) APP PHARMACEUTICALS INC (NASDAQ: APPX ) ARPIDA AG (SWX, Switzerland: ARPN) BTG (London Main Market, U.K.: BGC) CYTOS BIOT...

Naglazyme Approved by Japanese Ministry of Health

...l Inc. (Nasdaq and SWX: BMRN) announced today that anges MG, Inc. (AnGes), BioMarin's marketing and distrib...ridosis VI ( MPS VI). "We are proud to work with anges in bringing the first drug treatment option to MPS...reement with AnGes in December 2006, through which anges obtained exclusive rights to market Naglazyme in t...

Japanese Continue Relentless Biotech Stake in Midwest

...ining their university roles. This change alone has stimulated a proliferation of new biotech companies. One notable example is the biotech company anges MG, which listed its stock in September 2002 and was started by Ryuichi Morishita, an assistant professor at Osaka University (one of the prestigious ...

More>>

Other Tags
(Date:6/18/2013)... The Temp1000IS temperature data logger is ... be used to automatically record temperatures between -20 and ... comes with the serial number and device name engraved. ... separately) docking station and can be placed directly into ... of end-caps to download data. The small size of ...
(Date:6/18/2013)... Palo Alto has taken yet another step ... with its recent major long-term solar power commitment. , ... electric power purchase agreements , which together will result in ... photovoltaic electric power per year, which is the equivalent of ... enough power to supply all 65,000+ Palo Alto residents---and then ...
(Date:6/18/2013)... Internationally acclaimed plastic surgeon, Dr. John ... his unique approach to breast augmentation. Dr. Tebbetts’ ... method and highlights the results of Dr. Tebbetts’ ... Tebbetts compares his breast augmentation method to other ... does not necessitate the use drains, bandages, narcotic ...
(Date:6/18/2013)... signaling network between two previously unconnected proteins, exposing a ... growth at its starting point. , A team led ... Cancer Center reported the tie between epidermal growth factor ... a protein vital to the first step in DNA ... . , "MCM7 overexpression marks cell proliferation and is ...
(Date:6/18/2013)... 2013 myCNAjobs announces the addition of ... articles, and tips to the Caregiver Resources Center. , ... the 10,000+ retiring baby boomers each day, the need ... job resources has never been greater. myCNAjobs, ... community, recently launched the first-ever free resource center for ...
Breaking Medicine News(10 mins):Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2
(Date:6/18/2013)... from the University of Adelaide shows that weight gain ... life is linked to a higher IQ at early school age. ... researchers, who analysed data from more than 13,800 children who were ... Pediatrics , show that babies who put on 40% of ... points higher by the time they were six years of age, ...
(Date:6/17/2013)... JOLLA, CA June 17, 2013 An international ... (TSRI), the Howard Hughes Medical Institute and Albert Einstein ... highly promising new anti-tuberculosis compound that attacks the tuberculosis ... represent an effort to help solve one of the ... TB and its dangerous drug-resistant strains," said Peter G. ...
(Date:6/17/2013)... original foundations with more modern elements. Using this same ... P. Dietrich School of Arts and Sciences have designed ... gas storage, and gas transport more efficient and at ... latest issue of the Journal of the American ... work builds upon Pitt Associate Professor of Chemistry Nathaniel ...
Breaking Biology News(10 mins):IQ link to baby's weight gain in first month 2New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
Other Contents